<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751776/" ref="ordinalpos=3620&amp;ncbi_uid=5220562&amp;link_uid=PMC3751776" image-link="/pmc/articles/PMC3751776/figure/F2/" class="imagepopup">Figure 2.  From: Ibrutinib and novel BTK inhibitors in clinical development. </a></div><br /><div class="p4l_captionBody"><b>BTK signaling pathway.</b> BTK translocates to the plasma membrane by interacting with PIP3 to become membrane-bound where it undergoes sequential activation through trans-phosphorylation by Lyn and Syk kinases, followed by autophosphorylation. The downstream substrates of activated BTK and their associated signaling cascades are indicated.</div></div>